Basal Cell Carcinoma Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Basal Cell Carcinoma Treatment Market is segmented by Treatment Type (Surgery, Medication, Others), End-User, and Geography

Market Snapshot

basal-cell-carcinoma-treatment-market_Market Summary
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The basal cell carcinoma treatment market is anticipated to grow with a CAGR of 9.3% during the forecast period. The major factors attributing to the growth of the market are the increasing prevalence of skin malignancies, rise in various environmental factors, which leads to more UV exposure and increasing geriatric population who are more susceptible to skin diseases.

According to the Skin Cancer Foundation, about 90% of nonmelanoma skin cancers are correlated with exposure to ultraviolet radiation, and Basal cell carcinoma is the most common form of skin cancer. It is estimated that 4.3 million cases of BCC are diagnosed in the United States every year. However, high susceptibility of basal cell carcinoma to remain under-diagnosed and the high cost of the treatment are the constraints to the growth of the market.

Scope of the Report

As per the scope of the report, basal cell carcinoma is the type of skin cancer that begins in the basal cells, which produce new cells when the old ones die. The Basal Cell Carcinoma Treatment market is comprised of the Treatment Type, End-user, and Geography.

By Treatment Type
By End User
Specialty Clinics
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Surgery for Basal Cell Carcinoma is Expected to be the Fastest Growing Segment

The most common method used for the treatment of basal cell carcinoma is surgical excision. In this procedure, the surgeon cuts out the cancerous lesion and a surrounding margin of healthy skin. The surplus is inspected under a microscope to be sure there are no cancer cells. Excision might be recommended for basal cell carcinomas that are less likely to recur, such as those that form on the chest, back, hands, and feet.

Surgical excision has established to be more efficient due to its lowest possible recurrence rates, maximum cure rates, and top cosmetic results among all the treatment approach for basal cell carcinoma, leading to their high demand. It is expected that surgical excision to remain dominant over the next few years, confirming the dominance of the surgical segment.

According to the American Academy of Dermatology, it is expected that 95,830 noninvasive melanoma cases will be diagnosed in the United States in 2019, which pushes the growth of the market further.

Skin Cancer Rates

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall basal cell carcinoma treatment market, throughout the forecast period. This is due to the factors such as the rising incidence of geriatric population, rising awareness of advanced treatments, favorable reimbursement scenario, high prevalence of basal cell carcinoma in this region.

In the North America region, the United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of basal cell carcinoma in the country, is anticipated to stimulate the demand in this region. According to the American Academy of Dermatology, it is estimated that approximately 9,500 people in the United States are diagnosed with skin malignancies every day. Thus, rising cases of the skin malignacies expected propel the growth of the market.


Competitive Landscape

The Basal Cell Carcinoma Treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Merck & Co. Inc., Bausch Health Companies, F. Hoffmann-La Roche Ltd., Mylan N.V., Sun Pharmaceuticals Ltd., Allergan Inc., Perrigo Company plc, Strides Arcolab Ltd.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Skin Cancers

      2. 4.2.2 Increase in Geriatric Population

      3. 4.2.3 Environmental Factors Leading to Greater Exposure of UV Radiation

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

      2. 4.3.2 High Susceptibility of Basal Cell Carcinoma to remain Under-diagnosed

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Treatment Type

      1. 5.1.1 Surgery

      2. 5.1.2 Medication

      3. 5.1.3 Others

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Specialty Clinics

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Merck & Co. Inc

      2. 6.1.2 Bausch Health Companies Inc.

      3. 6.1.3 F. Hoffmann-La Roche AG

      4. 6.1.4 Sun Pharmaceuticals Ltd

      5. 6.1.5 Mylan N.V.

      6. 6.1.6 Abbvie (Allergan)

      7. 6.1.7 Perrigo Company plc

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Basal Cell Carcinoma Treatment Market market is studied from 2018 - 2026.

The Basal Cell Carcinoma Treatment Market is growing at a CAGR of 9.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Mylan N.V., Sun Pharmaceuticals Ltd., Merck & Co. Inc. are the major companies operating in Basal Cell Carcinoma Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!